PURE-02: An open-label, single-arm, feasibility study of neoadjuvant pembrolizumab before Radical Nephroureterectomy (RNU) in patients with high-risk, Upper-Tract Urothelial Carcinoma (UTUC)
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI